Current treatment of Hodgkin's disease (Q33947871)

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Angio-immunoblastic lymphadenopathy with dysproteinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Immunoblastic lymphadenopathy. A hyperimmune entity resembling Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A proposal for classification of lymphoid neoplasms (by the International Lymphoma Study Group)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic indicators of laparotomy findings in clinical stage I-II supradiaphragmatic Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors for positive surgical staging in patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Controversies in the use of diagnostic staging laparotomy and splenectomy in the management of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic groups for management of localized Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Leukemia following Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Splenectomy and the increasing risk of secondary acute leukemia in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Predictive value of lymphography for sites of subdiaphragmatic disease encountered at staging laparotomy in newly diagnosed Hodgkin's disease and non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Diagnostic imaging studies in patients with newly diagnosed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

New diagnostic imaging procedures in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Role of the gallium scan in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The gallium scan predicts relapse in patients with Hodgkin's disease treated with combined modality therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Comparison of gallium scan, computed tomography, and magnetic resonance in patients with mediastinal Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Gallium scans in the management of patients with Hodgkin's disease: a study of 101 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Gallium scans in patients with mediastinal Hodgkin's disease treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Diagnostic accuracy of ultrasound and computed tomography in the staging of Hodgkin's disease. Verification by laparotomy in 100 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Ultrasound examination of pathological cervical lymph nodes in patients with non-Hodgkin's lymphoma and Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Erythrocyte sedimentation rate predicts early relapse and survival in early-stage Hodgkin disease. The EORTC Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Bone marrow involvement in Hodgkin's disease: an analysis of 135 consecutive cases. German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Role of staging bone marrow examination in children with Hodgkin disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Bone marrow examination in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of erythrocyte sedimentation rate in clinical stages I-II of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Evolution of erythrocyte sedimentation rate as predictor of early relapse in posttherapy early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

National survey of patterns of care for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease prognosis: a directly predictive equation.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The results of radiotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Mantle irradiation in Hodgkin's disease. An analysis of technique, tumor eradication, and complications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Limited extranodal Hodgkin's disease. Unfavorable prognosis and therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease, stages I and II.Relationship of recurrence to size of disease, radiation dose, and number of sites involved

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of mediastinal involvement in Hodgkin's disease treated with curative radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Bulky mediastinal Hodgkin's disease management and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The EORTC treatment of early stages of Hodgkin's disease: the role of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A multivariate analysis of prognostic factors in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Stage III Hodgkin's disease: improved survival with combined modality therapy as compared with radiation therapy alone

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors for Stage IV Hodgkin's disease treated with MOPP, with or without bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Stage IA to IIB supradiaphragmatic Hodgkin's disease. Long-term survival and relapse frequency

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Twenty years of MOPP therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease: a reassessment of prognostic factors following modification of radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Radiation therapy for pathologic stage III Hodgkin's disease with and without chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

ChlVPP combination chemotherapy for Hodgkin's disease: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Curative radiotherapy for laparotomy-staged IA, IIA, IIIA Hodgkin's disease: an evaluation of the gains achieved with radical radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Patterns of relapse in stages I, II and IIIA Hodgkin's disease: Influence of initial therapy and implications for the future

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic risk factors in advanced Hodgkin's lymphoma. Report of the German Hodgkin Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The significance of mediastinal involvement in early stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Mediastinal involvement in early-stage Hodgkin's disease. Response to treatment and pattern of relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Evaluation of the significance of prognostic factors in stage III Hodgkin's disease treated with MOPP and radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Further follow-up of results of treatment in 90 laparotomy-negative stage I and II Hodgkin's disease patients: significance of mediastinal and non-mediastinal presentations

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Supradiaphragmatic Hodgkin's disease: significance of large mediastinal masses

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of large mediastinal involvement in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The management of stage II supradiaphragmatic Hodgkin's disease at St. Bartholomew's Hospital. A retrospective review of 114 previously untreated patients over 14 years

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A randomized study comparing chemotherapy alone with chemotherapy followed by radiotherapy in patients with pathologically staged IIIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The prognostic significance of mediastinal bulk in patients with stage IA-IVB Hodgkin's disease: a report from the Manchester Lymphoma Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of mediastinal mass in adult Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Laparotomy-staged IA versus IIA Hodgkin's disease. A comparative study with evaluation of prognostic factors for stage IIA disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combined modality therapy for mediastinal Hodgkin's disease. Prognostic significance of constitutional symptoms and size of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Radiation therapy in clinical stage I and II Hodgkin's disease. The Princess Margaret Hospital Lymphoma Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Stage I to IIB Hodgkin's disease: the combined experience at Stanford University and the Joint Center for Radiation Therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Results of treatment of stage IA and IIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of lymphography in stage IIIs Hodgkin's disease (HD)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Patterns of relapse in advanced Hodgkin's disease treated with combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic significance of tumour burden in Hodgkin's disease PS I and II

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Systemic disturbance in Hodgkin's disease and its relation to histopathology and prognosis (BNLI report No. 30).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Tumour burden in early stage Hodgkin's disease: the single most important prognostic factor for outcome after radiotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease stages I and II with infradiaphragmatic presentation: a rare and prognostically unfavourable combination

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors in Hodgkin's disease stage III with special reference to tumour burden

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Tumor burden as the most important prognostic factor in early stage Hodgkin's disease.Relations to other prognostic factors and implications for choice of treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Tumour burden as the main indicator of prognosis in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease: a clinicopathologic study of 659 cases

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Extended versus involved fields irradiation combined with MOPP chemotherapy in early clinical stages of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Relationship of histological subtypes to prognosis in early stage Hodgkin's disease: a review of 312 cases in a controlled clinical trial. The Groupe Pierre et Marie Curie.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The prognostic significance of cellular subtypes in nodular sclerosing Hodgkin's disease: an analysis of 271 non-laparotomised cases (BNLI report no. 22).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. A study of 1659 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Histopathologic grading of nodular sclerosis Hodgkin's disease. Lack of prognostic significance in 254 surgically staged patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Lymphocyte predominant Hodgkin's disease--a workshop report. European Task Force on Lymphoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Value of serum copper measurement in lymphomas and several other malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Serum copper in Hodgkin's disease in children

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The clinical usefulness of serum copper determinations in Hodgkin's disease. A retrospective study of 241 patients from 1963-1973

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The prognostic value of HLA phenotypes in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic value of blood glucose in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Multivariate analysis of T-cell functional defects and circulating serum factors in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Soluble interleukin-2 receptors in the serum of patients with Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Serum albumin in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Serum levels of soluble CD30 molecule (Ki-1 antigen) in Hodgkin's disease: relationship with disease activity and clinical stage

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A review and interpretation of cytogenetic abnormalities identified in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease and Epstein-Barr virus.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Epstein-Barr virus in Hodgkin disease. Relation to age and subtype.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Epidemiology of EBV and Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

EBV infection patterns in Hodgkin's disease and normal lymphoid tissue: expression and cellular localization of EBV gene products

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A pathologic study of Hodgkin's disease in Korea and its association with Epstein-Barr virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors in Hodgkin's disease with special reference to age

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The prognostic significance of age in patients with advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combination Chemotherapy in the Treatment of Advanced Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The chemotherapy of Hodgkin's disease: past experiences and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Cyclical combination chemotherapy and gonadal function. Retrospective study in males

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Male gonadal dysfunction in Hodgkin's disease. A prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Long term remissions with combined modality therapy for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A combination of chlorambucil, vinblastine, procarbazine and prednisolone for treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Ch1VPP—An Effective and Well-Tolerated Alternative to MOPP Therapy for Hodgkinʼs Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

MVPP chemotherapy regimen for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combined chemotherapy cyclophosphamide, vinblastine, procarbazine and prednisone (CVPP) V.S. CVPP PLUS CCNU (CCVPP) in Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Randomized trial of CVPP for three versus six cycles in favorable-prognosis and CVPP versus AOPE plus radiotherapy in intermediate-prognosis untreated Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

[Vinblastine + procarbazine + cyclophosphamide association in the treatment of Hodgkin's disease (author's transl)]

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Treatment of Hodgkin's disease, clinical stage I and II. Results obtained in 100 patients by combination of 1 or 2 cycles of chemotherapy with radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

BCNU, velban, cyclophosphamide, procarbazine, and prednisone (BVCPP) in advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

LOPP alternating with EVAP is superior to LOPP alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combination therapy for advanced resistant Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Intercurrent death after Hodgkin disease therapy in radiotherapy and adjuvant MOPP trials

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Second cancer after the treatment for Hodgkin's disease: a report from the International Database on Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Incidence of second cancers in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Risk of therapy-related leukaemia and preleukaemia after Hodgkin's disease. Relation to age, cumulative dose of alkylating agents, and time from chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Leukemia after therapy with alkylating agents for childhood cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Second acute leukemia and other malignancies following treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

A randomized study in stage IIIB and IV Hodgkin's disease comparing eight courses of MOPP versus an alteration of MOPP with ABVD: a European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group and Groupe Pierre-et-Marie-Curi

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Current strategies for early Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combination of ABVD and radiotherapy in early stages of Hodgkin's disease: analysis of a series of 94 patients. Pierre and Marie Curie Group (GPMC)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Coronary heart disease mortality after irradiation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Coronary artery disease mortality in patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Symptomatic coronary artery disease after mantle irradiation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Late complications after Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Pharmacokinetics and metabolism of epirubicin during repetitive courses of administration in Hodgkin's patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Novel combination of epirubicin, bleomycin, vinblastine and prednisone (EBVP II) before radical radiotherapy in localized stages (I-IIIA) of Hodgkin's disease. Early results in 100 consecutive patients. Pierre-et-Marie-Curie Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Preliminary results of the EORTC-GPMC controlled clinical trial H7 in early-stage Hodgkin's disease. EORTC Lymphoma Cooperative Group. Groupe Pierre-et-Marie-Curie

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Alternating non-cross-resistant combination chemotherapy or MOPP in stage IV Hodgkin's disease. A report of 8-year results.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease: ten-year results

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Treatment of advanced Hodgkin's disease with chemotherapy--comparison of MOPP/ABV hybrid regimen with alternating courses of MOPP and ABVD: a report from the National Cancer Institute of Canada clinical trials group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Brief chemotherapy associated with extended field radiotherapy in Hodgkin's disease. Long-term results in a series of 102 patients with clinical stages I–IIIA

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease treated by chemotherapy and large field irradiation. Hematologic effects

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Vinblastine, bleomycin, and methotrexate: an effective adjuvant in favorable Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The Stanford experience with combined procarbazine, Alkeran and vinblastine (PAVe) and radiotherapy for locally extensive and advanced stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Results of CAV regimen (CCNU, Melphalan, and VP-16) as third-line salvage therapy for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

CEP regimen (CCNU, etoposide, prednimustine) for relapsed/refractory Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Long-term follow-up of advanced Hodgkin's disease patients treated with a combination of streptozotocin, lomustine (CCNU), doxorubicin and bleomycin (SCAB).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

'VEEP' in children with Hodgkin's disease--a regimen to decrease late sequelae

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

PACE BOM chemotherapy: a 12-week regimen for advanced Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Brief chemotherapy, Stanford V, and adjuvant radiotherapy for bulky or advanced-stage Hodgkin's disease: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

BEACOPP: an intensified chemotherapy regimen in advanced Hodgkin's disease. The German Hodgkin's Lymphoma Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Early autologous bone marrow transplantation (ABMT) in the treatment of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Dexa-BEAM in patients with Hodgkin's disease refractory to multidrug chemotherapy regimens: a trial of the German Hodgkin's Disease Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The MINE regimen as intensive salvage chemotherapy for relapsed and refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Non-Hodgkin's lymphoma arising in patients treated for Hodgkin's disease in the BNLI: a 20-year experience. British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Occurrence of Non-Hodgkin's Lymphoma after Therapy for Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Second cancer risk following Hodgkin's disease: a 20-year follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Effect of treatment for Hodgkin's disease on pulmonary function: results of a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Thyroid, pulmonary, and cardiac sequelae after treatment for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Lung function impairment in long-term survivors of Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

The Radical Radiotherapy of Regionally Localized Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease: unfolding concepts concerning its nature, management and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Radiation-associated breast cancer after Hodgkin's disease: risks and screening in perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Risk of second primary cancers after Hodgkin's disease by type of treatment: analysis of 2846 patients in the British National Lymphoma Investigation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Risk of second primary cancer after Hodgkin's disease in patients in the British National Lymphoma Investigation: relationships to host factors, histology and stage of Hodgkin's disease, and splenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Breast cancer after treatment of Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Breast cancer and other second neoplasms after childhood Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High risk of breast carcinoma after irradiation of young women with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Myocardial infarction in young patients with Hodgkin's disease ? potential pothogenic role of radiotherapy, chemotherapy, and splenectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Cardiac disease following treatment of Hodgkin's disease in children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Cardiac lesions after mediastinal irradiation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Long-term effects on pulmonary function of mantle radiotherapy in patients with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Late cardiac effects of therapeutic mediastinal irradiation. Assessment by echocardiography and radionuclide angiography

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Echocardiographic abnormalities following cardiac radiation

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

MOPP chemotherapy plus irradiation for Hodgkin's disease, stages IA to IIIB. Long-term results of the prospective trial H72 (1972-1976, 334 patients)

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Low-dose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combined modality treatment with low-dose radiation and MOPP chemotherapy for children with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Efficacy and toxicity of multiagent chemotherapy and low-dose involved-field radiotherapy in children and adolescents with Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

MOPP chemotherapy versus extended-field radiotherapy in the management of pathological stages I-IIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

ABVD/MOPP and low-dose involved-field radiotherapy in pediatric Hodgkin's disease: the Stanford experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Patients with stage III/IV Hodgkin's disease in partial remission after MOPP/ABV chemotherapy have excellent prognosis after additional involved-field radiotherapy: interim results from the ongoing EORTC-LCG and GPMC phase III trial. The EORTC Lymph

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Late relapse in early-stage Hodgkin's disease patients enrolled on European Organization for Research and Treatment of Cancer protocols

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Late relapse among patients treated for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors for patients relapsing after radiotherapy for early-stage Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors for patients with Hodgkin disease in first relapse

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Salvage of relapse of patients with Hodgkin's disease in clinical stages I or II who were staged with laparotomy and initially treated with radiotherapy alone. A report from the international database on Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Early bone marrow transplantation in Hodgkin's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Treatment strategies for patients with relapsed or refractory Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Autologous bone marrow transplantation for Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High dose chemotherapy followed by autologous hematopoietic rescue in Hodgkin's disease: long-term follow-up in 128 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registry

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High-dose therapy and autologous bone marrow transplantation for hodgkin's disease patients with relapses potentially treatable by radical radiation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Intensive therapy and autologous stem cell transplantation for Hodgkin's disease in first relapse after combination chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO cooperative group

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High-dose cytotoxic therapy and bone marrow transplantation for relapsed Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

High-dose chemotherapy with autologous bone marrow transplantation in 50 advanced resistant Hodgkin's disease patients: an Italian study group report.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin's disease patients in first remission after MOPP/ABVD chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Early intensive therapy with autotransplantation for high-risk Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Treatment of Hodgkin's disease in children with alternating mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) and adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) courses without radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in the elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin disease in patients 60 years of age or older. Histologic and clinical features of advanced-stage disease. The Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in patients over sixty years old

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in the elderly. A series of 30 patients aged older than 70 years

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease and pregnancy

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Management of the Pregnant Patient with Hodgkin's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Radiotherapy during pregnancy for clinical stages IA-IIA Hodgkin's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Increased Incidence of Hodgkin Disease in Homosexual Men with HIV Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985-1991. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Cancer incidence in a cohort of human immunodeficiency virus seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in 92 patients with HIV infection: The Italian experience

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease during HIV1 infection: the French registry experience. French Registry of HIV-associated Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease and human immunodeficiency virus infection: clinicopathologic and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Human immunodeficiency virus associated Hodgkin's disease: report of 45 cases from the French Registry of HIV-Associated Tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin disease and HIV

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Human immunodeficiency virus-associated Hodgkin's disease. Clinicopathologic studies of 24 cases and preponderance of mixed cellularity type characterized by the occurrence of fibrohistiocytoid stromal cells

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease associated with human immunodeficiency virus infection. A clinical study of 46 cases. Cooperative Study Group of Malignancies Associated with HIV Infection of Madrid

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Combined antineoplastic and antiretroviral therapy for patients with Hodgkin's disease and human immunodeficiency virus infection. A prospective study of 17 patients. The Italian Cooperative Group on AIDS and Tumors (GICAT).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in patients with HIV infection and in the general population: comparison of clinicopathological features and survival

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Intracerebral Hodgkin's disease in a human immunodeficiency virus-seropositive patient

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021

Hodgkin's disease in 63 intravenous drug users infected with human immunodeficiency virus. Gruppo Italiano Cooperativo AIDS & Tumori (GICAT).

1 reference

https://api.crossref.org/works/10.1016%2FS1040-8428%2899%2900070-0

7 January 2021